DIDRONEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIDRONEL (DIDRONEL).
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, reducing osteoclast activity and inducing osteoclast apoptosis.
| Metabolism | Not metabolized; excreted unchanged via renal tubular secretion. |
| Excretion | Renal: 50% unchanged; fecal/biliary: negligible; absorbed drug not excreted renally is retained in bone with slow release. |
| Half-life | Terminal elimination half-life ranges from hours to weeks; initial phase 2-6 hours, deep bone phase up to several weeks due to slow release from bone. |
| Protein binding | Unbound; negligible binding (<1%) to plasma proteins. |
| Volume of Distribution | Vd approximately 1.5 L/kg; extensive distribution into bone mineral (hydroxyapatite). |
| Bioavailability | Oral: 1-6% (dose-dependent, saturated absorption); absorption decreases with food or calcium-containing products. |
| Onset of Action | Oral: inhibition of bone resorption begins within days; clinical effect (e.g., reduced bone turnover) measurable after 1-2 weeks. |
| Duration of Action | Effect persists for weeks to months after discontinuation due to prolonged bone binding; single dose effect lasts up to 4-6 weeks. |
| Molecular Weight | 250.09 |
For Paget disease: 5 mg/kg orally once daily for 6 months, or 5 mg/kg orally once daily for 3 months if retreatment; for heterotopic ossification: 20 mg/kg orally once daily for 2 weeks pre- and 3 months post-surgery; for hypercalcemia of malignancy: 5-10 mg/kg orally once daily for up to 6 months.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if CrCl < 30 mL/min; for CrCl 30-79 mL/min, reduce dose by 50%; no adjustment needed if CrCl ≥ 80 mL/min. |
| Liver impairment | No adjustment required for mild-to-moderate hepatic impairment; not studied in severe impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established; no specific weight-based dosing recommended. |
| Geriatric use | No specific dose adjustment; monitor renal function due to age-related decline; use with caution if CrCl < 30 mL/min. |
| 1st trimester | Avoid due to potential fetal harm from bisphosphonate accumulation in bone; animal studies show skeletal abnormalities. |
| 2nd trimester | Avoid; risk of fetal hypocalcemia and skeletal effects; limited human data. |
| 3rd trimester | Avoid; may cause neonatal hypocalcemia and skeletal abnormalities; discontinue if pregnancy occurs. |
Clinical note
Comprehensive clinical and safety monograph for DIDRONEL (DIDRONEL).
| Placental transfer | Crosses placenta in animals; likely in humans based on molecular weight and bisphosphonate class. |
| Breastfeeding | Excreted in animal milk; unknown in humans. Avoid breastfeeding due to potential bone growth effects in infant. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
HypocalcemiaRenal impairment (CrCl <30 mL/min)OsteomalaciaHypersensitivity to etidronate disodium
| Precautions | Renal impairment (risk of acute renal failure; monitor renal function before and during therapy), Hypocalcemia (correct before initiation; ensure adequate calcium and vitamin D intake), Osteonecrosis of the jaw (especially with dental procedures; perform dental exam before therapy if risk factors present), Severe musculoskeletal pain (discontinue if severe), Hypersensitivity reactions (urticaria, angioedema) |
| Food/Dietary | Avoid food, beverages (except plain water), and calcium-rich foods (milk, yogurt, cheese) for at least 2 hours before and after dosing. High-calcium foods can significantly reduce absorption. |
Loading safety data…
| L5 |
| Teratogenic Risk | Pregnancy Category C. Etidronate disodium (DIDRONEL) has been associated with skeletal abnormalities in animal studies. In humans, bisphosphonates may cause fetal harm when administered during pregnancy, particularly during the second and third trimesters due to potential effects on fetal bone mineralization. Use is not recommended during pregnancy. |
| Fetal Monitoring | Monitor serum calcium, phosphate, and renal function periodically. In pregnant women, consider fetal ultrasound to assess bone development if exposure occurs. |
| Fertility Effects | Etidronate has been shown to cause decreased fertility in animal studies. In humans, no adequate data are available; however, bisphosphonates may potentially impair fertility due to effects on calcium metabolism and bone turnover. |
| Clinical Pearls | Administer on an empty stomach at least 2 hours before or after food; avoid concurrent calcium, antacids, or iron supplements. Monitor renal function before each dose due to risk of renal impairment. In Paget's disease, initiate with 5 mg/kg/day for 6 months, then reassess. For heterotopic ossification, start 20 mg/kg/day 2 weeks before surgery and continue 4 weeks post-op. Dose reductions required in renal impairment (CrCl <35 mL/min). |
| Patient Advice | Take this medication on an empty stomach, at least 2 hours before or after any food, drink, or other medications. · Do not take with calcium supplements, antacids, or iron-containing products as they reduce absorption. · Drink a full glass of water with each dose to help prevent throat or stomach irritation. · Report any new or worsening bone pain, difficulty swallowing, or signs of kidney problems (decreased urination, swelling). · Complete full course as prescribed; do not skip doses even if feeling well. |